Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

People with PBC often have increased levels of ALP in their blood. This can be an early sign of the disease before they develop noticeable symptoms of liver problems. It isn’t known yet whether ...

NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

The ability to identify a subset of T cells linked to tissue auto-reactivity in blood opens important prospects for the development of biomarkers and therapies. CD4 T-cells circulating in the blood ...

One place this happens is around the belly button, where tiny veins in the abdominal wall expand and become visible under the ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...